Glasdegib plus low-dose cytarabine for acute myeloid leukemia: Practical considerations from advanced practitioners and pharmacists

OBJECTIVE: Acute myeloid leukemia (AML) is primarily a disease of older adults. These patients may not be candidates for intensive treatment, and there has been an ongoing need for treatment options for this group. We review the use of glasdegib, a hedgehog-pathway inhibitor available for use in com...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Oncol Pharm Pract
Glavni autori: Relias, Valerie, McBride, Ali, Newman, Matthew J, Paul, Shilpa, Saneeymehri, Seyyedeh, Stanislaus, Genique, Tobin, Jennifer, Hoang, Caroline J, Ryan, Joanne C, Galinsky, Ilene
Format: Artigo
Jezik:Inglês
Izdano: SAGE Publications 2020
Teme:
Review Articles
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8008421/
https://ncbi.nlm.nih.gov/pubmed/33215562
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1078155220973737
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items